Lexeo Therapeutics, Inc. LXEO
We take great care to ensure that the data presented and summarized in this overview for Lexeo Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in LXEO
Top Purchases
Top Sells
About LXEO
Insider Transactions at LXEO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 17
2025
|
Kyle Rasbach Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,875
+50.0%
|
-
|
|
Jan 07
2025
|
Eric Adler Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+38.25%
|
-
|
|
Jan 07
2025
|
Tai Sandi See Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,750
+41.17%
|
-
|
|
Jan 07
2025
|
Jenny Robertson Chief Legal & Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,250
+37.66%
|
-
|
|
Jan 07
2025
|
Jose Manuel Otero Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,250
+31.34%
|
-
|
|
Jan 07
2025
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
103,750
+31.61%
|
-
|
|
Dec 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,500
-2.03%
|
$20,000
$8.2 P/Share
|
|
Dec 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+1.99%
|
$5,000
$2.33 P/Share
|
|
Nov 25
2024
|
Paula H Cholmondeley |
BUY
Open market or private purchase
|
Direct |
15,000
+32.88%
|
$90,000
$6.99 P/Share
|
|
Nov 11
2024
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,500
-2.03%
|
$17,500
$7.82 P/Share
|
|
Nov 11
2024
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+1.99%
|
$5,000
$2.33 P/Share
|
|
Oct 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,000
-3.98%
|
$40,000
$8.1 P/Share
|
|
Oct 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.83%
|
$10,000
$2.33 P/Share
|
|
Sep 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,000
-3.98%
|
$50,000
$10.65 P/Share
|
|
Sep 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.83%
|
$10,000
$2.33 P/Share
|
|
Aug 12
2024
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,000
-3.98%
|
$55,000
$11.53 P/Share
|
|
Aug 12
2024
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.83%
|
$10,000
$2.33 P/Share
|
|
Jul 11
2024
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
28,031
-9.43%
|
$504,558
$18.06 P/Share
|
|
Jul 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
26,969
-7.82%
|
$431,504
$16.65 P/Share
|
|
Jul 10
2024
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+2.77%
|
$10,000
$2.33 P/Share
|
Last 12 Months Summary
Buy / Acquisition
398K
Shares
From
8
Insiders
| Open market or private purchase | 15K shares |
|---|---|
| Grant, award, or other acquisition | 348K shares |
| Exercise of conversion of derivative security | 35K shares |
Sell / Disposition
85K
Shares
From
1
Insiders
| Open market or private sale | 85K shares |
|---|